Elixir Pharmaceuticals (Cambridge, MA) a late-stage pharmaceutical company focused on the treatment of metabolic diseases such as diabetes and obesity, closed a $12M Series D financing. Participants include MPM Capital, Arch Venture Partners, Oxford Bioscience Partners, Omega Funds and Physic Ventures.

ProteoStasis Therapeutics (Cambridge, MA) developing therapies to treat multiple genetic and degenerative disorders associated with protein homeostasis deficiencies, closed a $45M Series A financing. Participants include HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures.

InteKrin Therapeutics (Los Altos, CA) clinical-stage biopharmaceutical company focused on the development of products for diabetes, metabolism and obesity, closed a $20M Series C financing. Participants include Skyline Ventures, Sofinnova Ventures, OrbiMed Advisors, , Sears Capital Management and Vivo Ventures.

Dicerna Pharmaceuticals (Watertown, MA) clinical-stage biopharmaceutical company developing RNAi therapeutics for multiple clinical applications, closed a $8.4M Series A. Participants include Abingworth, Oxford Bioscience Partners and Skyline Ventures.

Medipacs (Tucson, AZ) early-stage drug infusion device company using hydrogel polymers to regulate distribution of medicine, closed a $1.7M Series A financing. Participants included Mesa Verde Venture Partners.

Arcion Therapeutics (Baltimore, MD) a clinical stage biotechnology company focused on the development of new, targeted treatments for severe pain treatment in diabetic neuropathy and post-herpetic neuralgia closed a $8.8M Series A financing. Participants include CMEA Ventures and InterWest Partners.

Escoublac (Cambridge, MA) the first occupant in Biogen Idec new Innovation Incubator is developing treatments for metabolic diseases, type II diabetes and obesity, closed a $6.7M Series A financing. Participants include Biogen Idec.

Phenomix (San Diego, Calif.) a drug discovery and development company focused on the treatment of Type 2 diabetes and hepatitis C raised a $55M Series C financing. The deal was led by Nomura Phase4 and joined by JPMorgan, Delphi Ventures, Baker Brothers, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Novartis Venture Fund and [...]

 
Intarcia Therapeutics (Emeryville, CA) a biopharmaceutical company developing therapies for Type 2 Diabetes and Hepatitis C raised $50M in a Series BB Financing. The round was led by New Leaf Venture, and joined by Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, and Granite Global Ventures.

Phenomix (San Diego, CA) a drug discovery and development company focused on novel drugs to inhibit therapeutic targets in the protease and kinase families.The most advanced programs are for treatment of Type 2 diabetes and for treatment of hepatitis C. The deal was led by Nomura Phase4 Ventures and was joined by JP Morgan Partners, [...]